In this episode of CardiaCast, Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals. They discuss available PCSK9 inhibitors, including the recently approved injectable PCSK9 inhibitor lerodalcibep-liga. After discussing the limitations and barriers associated with injectable PCSK9 inhibitors, they will introduce the emerging oral PCSK9 inhibitors and explore the latest clinical data for enlicitide and AZD0780.

This podcast was developed by the American College of Cardiology Foundation and Med-IQ and supported by an educational grant from Merck.

This episode is part of ACC's ongoing initiative to advance education on remote hemodynamic monitoring in heart failure management. Drs. Michael Zile, JoAnn Lindenfeld, and William Abraham explore the core capabilities of these devices and how emerging innovations aim to address current limitations. The conversation highlights how clinicians can interpret pressure data and define optimal targets, incorporates the growing role of direct-to-patient communication, and concludes with practical strategies for integrating device-generated insights into clinical workflows to improve patient outcomes.

This podcast is part of the ACC's  Pulmonary Artery Pressure Monitoring: Transforming HF Patient Care initiative, supported by Abbott.

In this episode, Drs. Christie Ballantyne and Eugenia Gianos discuss updates regarding the management of dyslipidemia released in new guidelines from the ACC and AHA Joint Committee on Clinical Practical Guidelines. Drs. Ballantyne and Gianos highlight the risks associated with high LDL-C levels and recent developments in clinical guidelines for patients who meet specific criteria for diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH) and heterozygous familial hypercholesterolemia (HeFH). Up-to-date therapies are explored in depth.

To visit the course page for the Familial Hypercholesterolemia: Improving Detection to Accelerate Treatment, click here!

In this episode, Drs. Ahmad Masri and Kevin Alexander review emerging clinical data in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at the Heart Failure Society of America Annual Scientific Meeting and the American Heart Association Scientific Sessions 2025, including key findings from the ATTRibute-CM and HELIOS-B trials. The discussion highlights recent publications evaluating currently available disease-modifying therapies. Drs. Masri and Alexander translate these new data into practical insights for clinicians, focusing on how evolving evidence may influence treatment selection, therapeutic sequencing, and integration of disease-modifying therapies into everyday clinical practice.

In this episode, Gregory Piazza, MD, FACC, Elvira Grandone, MD, PhD, and Abbey R. Kruper, PsyD, ABPP walk through the clinical and emotional challenges of the link between thrombosis and fertility. They discuss how clotting disorders can influence infertility, what this means for future thrombotic and cardiovascular risk, and how to support patients who are already managing significant stress. The faculty also outlines practical guidance for counseling patients who have experienced thrombosis during pregnancy or assisted reproductive therapy and who want to continue growing their families.

In this episode, Drs. Christie Ballantyne and Anne Goldberg discuss updates on familial hypercholesterolemia (FH) diagnosis and management. Recent publications in January 2026 in the Journal of Clinical Lipidology and The Journal of Pediatrics address refined diagnostic criteria and special populations including children and pregnant women. In this podcast episode, Drs. Ballantyne and Goldberg discuss the importance of early detection, genetic testing, and treatment.

To visit the course page for the Familial Hypercholesterolemia: Improving Detection to Accelerate Treatment, click here!

In this podcast, Drs. Michelle Kittleson and Jan Griffin provide a practical overview of evaluation and management of transthyretin amyloid cardiomyopathy (ATTR-CM) based on ACC's 2025 Concise Clinical Guidance document the Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. The experts elaborate on key takeaways, including identifying cardiac and extra-cardiac features that raise suspicion, outlining the diagnostic pathway and screening strategies, and utilizing current disease-modifying therapies and heart failure management. Guidance on monitoring, determining treatment candidacy, and emerging future therapies is also discussed.

This podcast is supported by an educational grant from BridgeBio.

ACC Chief Innovation Officer Dr. Ami Bhatt brings together Drs. Alexandre Almorad and Christopher Porterfield to discuss how advancements in pulsed field ablation (PFA) are transforming atrial fibrillation treatment. In this episode, the participants break down the latest research in PFA and explain what that means for the procedure's safety and effectiveness.

This podcast is supported by Johnson & Johnson.

Subscribe to CardiaCast